February 10, 2015
By Krystle Vermes, BioSpace.com Breaking News Staff
Erik Nordkamp has been named the new managing director and head of global innovative pharmaceutical business for Pfizer Inc. U.K., according to news coming from the biopharmaceutical company on Feb. 9. Nordkamp will be taking over for Jonathan Emms, who was appointed as the global marketing lead for Pfizer’s Global Established Pharmaceutical business.
“I have thoroughly enjoyed leading the Pfizer U.K. business and it’s been a great privilege to serve as ABPI president this past year,” said Emms. “I’m proud of what has been achieved in both roles and I’d like to see dialogue continue with [the] government in order to improve access and uptake of innovative medicines for U.K. patients, and achieve [the] government’s aspiration of making the U.K. a leader in life sciences.”
Nordkamp joined Pfizer back in 2010, and he has been working with Pfizer Greece, Cyprus and Malta over the past year. Before coming to Pfizer, Nordkamp was the president of PhRMA Innovation, a trade association.
“I am delighted to be returning to the U.K., a key global hub for scientific innovation,” said Nordkamp. “However, with a National Health Service under strain, the U.K. is in a situation where patients are not always able to gain access to the most innovative medicines. Industry can play a vital role in finding solutions to these challenges, and I look forward to continuing conversations with [the] government, the NHS and NICE to ensure the value of our industry is recognized, and health is seen as a longer term investment rather than a short-term cost.”
Looking Ahead to the Coming Months
As Pfizer re-arranges its personnel, the company is looking ahead ahead to a more promising 2015 after a challenging 2014. In its 2014 fourth quarter report, Pfizer noted that it faced higher charges for legal matters and a higher effective tax rate. Additionally, its reported revenues decreased $2 billion over the course of 2014, compared to the 2013 full-year report.
“During 2014, despite significant continued revenue headwinds from product losses of exclusivity and co-promote expiries, we were able to deliver modest adjusted diluted EPS growth,” said Pfizer CEO Ian Read. “As we look forward to 2015, we expect continued momentum with our pipeline, notably the potential U.S. approval of Ibrance for advanced breast cancer, as well as anticipated strong growth in emerging markets and from our recent product launches in developed markets, including Eliquis, Xeljanz, Prevnar 13 in adults and Nexium 24HR.”
BioSpace Temperature Poll
Who Do You Think Will Be Sanofi’s New CEO? French drugmaker Sanofi said Thursday that it will name a new chief executive in mere weeks, as it attempted to put to rest rumors that the company could not find any executives willing to take the reins after it unceremoniously ousted its previous CEO last fall. Who do you think will soon be crowned king? BioSpace wants your opinion!
